Skip to content

The value of broad chest aerosol in convalescent patients with ischemic stroke

The value of broad chest aerosol in convalescent patients with ischemic stroke

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200067018
Enrollment
Unknown
Registered
2022-12-23
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke(period of recovery)

Interventions

treatment group:Secondary prevention and treatment of cerebral infarction+Wide chest aerosol
control group:Secondary prevention and treatment of cerebral infarction

Sponsors

The Third People's Hospital of Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. Acute ischemic stroke was diagnosed 14-30 days before enrollment according to clinical symptoms, signs and head CT/ magnetic resonance examination; 3. The diagnosis of acute ischemic stroke met the diagnostic criteria in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018; 4. The onset of disease was more than 14 days, but less than 30 days; 5. The patient and his family members signed and agreed to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Transient ischemic attack (TIA); 2. Cerebral hemorrhage or subarachnoid hemorrhage; 3. Patients with ischemic stroke confirmed by examination to be caused by brain tumor, brain trauma, blood disease, etc.; 4. Patients with serious diseases of the heart, lung, liver, kidney, hematopoietic system, endocrine system and bone and joint diseases; 5. With severe depression, anxiety, mental disorders or severe dementia; 6. Patients with previous history of stroke and serious sequelae; 7. Patients with pre-stroke complicated with other diseases could not take care of themselves in daily life; 8. Pregnant and lactating patients; 9. Family members and patients refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
Magnetic resonance imaging of the skull;Daily Living Ability Rating Scale;National Institutes of Health Stroke Scale;The modified Rankin Scale;Hamilton Anxiety Scale, HAMA;Hamilton Depression Scale, HAMD;

Countries

China

Contacts

Public ContactZhang Zuyong

The Third People's Hospital of Hangzhou

zzynwk@126.com+86 135 1682 5005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026